Dopaminergic Influence on Thyrotropin Secretion in Primary Hypothyroidism

S. Reddy; A. Bhansali; R. Sialy; S. Masoodi; P. Dutta; S. Bhadada; R. Dash

doi:10.1055/s-2005-861472

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2005; 37(5): 286-289
DOI: 10.1055/s-2005-861472

Original Clinical

Dopaminergic Influence on Thyrotropin Secretion in Primary Hypothyroidism

S. Reddy¹ , A. Bhansali¹ , R. Sialy¹ , S. Masoodi¹ , P. Dutta¹ , S. Bhadada¹ , R. Dash¹

¹ Department of Endocrinology and Metabolism, Postgraduate Institute of Medical Education & Research, Chandigarh, India

Abstract

This study was conducted to assess the influence of dopamine on thyrotropin secretion in patients with primary hypothyroidism before and after optimized L-thyroxin replacement therapy. Thyrotropin responses to dopamine infusion (4 µg/kg/min over 3 hours) and IV metoclopramide (10 mg bolus), a dopamine receptor blocker were studied in 25 consecutive patients with primary hypothyroidism before and after achieving stable euthyroid state and compared with 15 normal age-matched controls. Thyrotropin response to both dopamine infusion (decremental) and IV metoclopramide bolus (incremental) was greater in patients with primary hypothyroidism than that in the control subjects. Thyrotropin response was greater in women than in men. The magnitude of decremental thyrotropin response to dopamine infusion and the incremental response to IV metoclopramide bolus significantly correlated with the basal T₃ and T₄ levels. Thyrotropin response was blunted to dopamine infusion but not to metoclopramide at follow-up after six-month replacement with L-thyroxin, and both the responses were comparable in women and men in patient group. We conclude that modulation of dopaminergic system by dopamine or by dopamine receptor blocker has a greater influence on thyrotropin secretion in patients with primary hypothyroidism than euthyroid normal subjects.

Key words

Dopamine - Metoclopramide - Primary hypothyroidism - Thyrotropin

Full Text

References

1 Jackson I M. Thyrotropin-releasing hormone. N Engl J Med. 1982; 306 145-155
2 Oppenheimer J H, Schwartz H L, Mariash C N, Kinlaw W B, Wong N CW, Freake H C. Advances in understanding of thyroid hormone action at the cellular level. Endocr Rev. 1987; 8 288-308
3 Lamberts S WJ, Zuyderwijk J, den Holder F, Koetsveld P V, Hofland L. Studies on the condition determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology. 1989; 50 44-50
4 Dieguez C, Foord S M, Peters J R, Hall R, Scanlon M F. Interactions among epinephrine, thyrotropin-releasing hormone, dopamine and somatostatin in the control of TSH secretion in vitro. Endocrinology. 1984; 114 957-961
5 Klibanski A, Milbury P E, Chin W W, Ridgway E C. Direct adrenergic stimulation of the release of thyrotropin and its subunits from the thyrotroph in vitro. Endocrinology. 1983; 113 1244-1249
6 Foord S M, Peters J, Scanlon M F, Rees Smith B, Hall R. Dopaminergic control of TSH secretion in isolated rat pituitary cells. FEBS Lett. 1980; 121 257-259
7 Foord S M, Peters J R, Dieguez C, Shewring G, Hall R, Scanlon M F. Thyrotropin regulates thyrotroph responsiveness to dopamine in vitro. Endocrinology. 1986; 118 1319-1326
8 Chen H J, Meites J. Effects of biogenic amines and TRH on release of prolactin and TSH in the Rat. J Clin Endocrinol Metab. 1975; 96 10-14
9 Feek C M, Sawers J SA, Brown N S, Seth J, Irvine W J, Toft A D. Influence of thyroid status on dopaminergic inhibition of thyrotropin and prolactin secretion. J Clin Endocrin Metab. 1980; 51 585-589
10 Rapoport B, Refetoff S, Fang V S, Friesen H G. Suppression of serum thyrotropin (TSH) by L-Dopa in chronic hypothyroidism. J Clin Endocrinol Metab. 1973; 36 256-262
11 Leblanc H, Lachelin G CL, Abu-Fadil S, Yen S SC. Effect of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocrinol Metab. 1976; 43 668-674
12 Burrow G N, May P B, Spaulding S W, Donabedian R K. TRH and dopamine interactions affecting pituitary hormone secretion. J Clin Endocrinol Metab. 1977; 45 65-67
13 Besses G S, Burrow G N, Spaulding S W, Donabedian R K. Dopamine infusion acutely inhibits the TSH and Prolactin response to TRH. J Clin Endocrinol Metab. 1975; 41 985-987
14 Zulewski H, Muller B, Exer P, Andre R, Staub J J. Estimation of tissue hypothyroidism by a new clinical score: Evaluation of Patients with various grades of Hypothyroidism and controls. J Clin Endocrinol Metab. 1997; 82 771- 776
15 Delitala G. Dopamine and TSH secretion in man. The Lancet. 1977; 8 760-761
16 Cooper D S, Klibanski A, Ridgway E C. Dopaminergic modulation of TSH and its subunits: In vivo and in vitro studies. Clin Endocrinology. 1974; 16 265-275
17 Refetoff S, Fang V S, Rapoport B, Friesen H G. Effect of L-dopa, TSH and thyroid hormone in various combinations. J Clin Endocrinol Metab. 1983; 38 450-456
18 Minozzi M, Faggiano M, Lombardi G. Carella C, Criscuolo T, Scapagnini U. Effect of L-Dopa on plasma TSH levels in primary hypothyroidism. Neuroendocrinology. 1975; 17 147-153
19 Scanlon M F, Weightman D R, Mora B, Heath M, Shale D J, Snow M H, Hall R. Evidence for dopaminergic control of thyrotropin secretion in man. Lancet. 1977; 27 421-423
20 Scanlon M F, Weightman D R, Shale D J, Mora B, Heath M, Snow M H, Lewis M, Hall R. Dopamine is a physiological Regulator of thyrotropin (TSH) secretion in normal man. Clinical endocrinology. 1979; 10 7-15
21 Pourmand N, Rodriguez-Arnao M D, Weightman D R, Hall R, Cook D B, Lewis M, Scanlon M F. Domperidone: A novel agent for the investigation of anterior pituitary function and control in man. Clinical endocrinology. 1980; 12 211-215
22 Faglia G, Beck-Peccoz P, Ferrari C, Ambrosi B, Spada A, Travalini P. Enhanced plasma thyrotropin response to thyrotropin releasing hormone following estradiol administration in man. Clinical Endocrinology. 1973; 2 207-210
23 Lloyd H M, Meares J D, Jacobi J. Early effects of stilboesterol on growth hormone and prolactin secretion and on mitotic activity in the male rat. J of Endocrinology. 1973; 58 227-231
24 Sowers J R, McCallum R W, Harshman J M, Sturdevant R AL, Meyer N. Comparison of metoclopramide with other dynamic tests of prolactin secretion. J Clin Endocrinol Metab. 1976; 43 679-681
25 Feek C M, Sawers J SA, Brown N S, Seth J, Irvine W J, Toft A D. Influence of thyroid status on dopaminergic inhibition of thyrotropin and prolactin secretion. J Clin Endocrinol Metab. 1980; 51 585-589
26 Scanlon M F, Weetman A P, Lewis M, Pourmand M, Rodriguez-Arnao M D, Weightman D R, Hall R. Dopaminergic modulation of circadian thyrotropin rhythms and thyroid hormone levels in euthyroid subjects. J Clin Endocrinol Metab. 1980; 51 1251-1256
27 Scanlon M F, Chan V, Health M, Pourmand M, Rodriguez-Arnao M D, Weightman O R, Lewis M, Hall R. Dopaminergic control of thyrotropin, α-subunit, β-subunits and prolactin in euthyroidism and hypothyroidism. J Clin Endocrinol Metab. 1981; 58 360-365
28 Spitz I M, Treslian S, Cohen H, Arnon N, Roith L D. Failure of metoclopramide to influence LH, FSH and TSH secretion or their responses to releasing hormones. Acta Endocrinologica. 1979; 92 640-647
29 Wayne F L, Louyse A L, Woolf P D. Dopamine affects basal and augmented pituitary Hormone Secretion. J Clin Endocrinol Metab. 1978; 47 480-487
30 Eddy R L, Jones A L, Chakmakjian H, Silverthorne M C. Effect of levadopa (L-DOPA) on human hypophyseal trophic hormone release. J Clin Endocrinol Metab. 1971; 33 709-712

Dr. Anil Bhansali

Dept. of Endocrinology · Postgraduate Institute of Medical Education and Research ·

Chandigarh-160012 · India

Phone: + 91 (172) 74 75 85-600, ext. 65 83

Fax: + 91 (172) 74 44 01, 74 50 78 ·

Email: anilbhansali_endocrine@rediffmail.com